Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma

Journal Article · Sun Oct 01 04:00:00 EDT 2006 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2006.04.059· OSTI ID:20850088

Meredith, Ruby F ^[1]; Knox, Susan J ^[2]

---

1. Department of Radiation Oncology, University of Alabama Medical Center, Birmingham, AL (United States)
2. Department of Radiation Oncology, Center for Advanced Medicine Clinical Cancer Center, Stanford, CA (United States)

Over the past several decades, several biomolecules have been investigated for their ability to deliver radiation to cancer cells, but antibodies have been the carriers of choice in systemic targeted radionuclide therapy (STaRT). Two radioimmunotherapy agents that target the CD20 antigen, {sup 131}I-tositumomab and {sup 9}Y-ibritumomab tiuxetan, have been approved by the U.S. Food and Drug Administration for the treatment of patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL), and clinical trials have shown that they are effective as monotherapies in the salvage setting, producing response rates that are often higher and durations of response that are often longer than those with chemotherapy. Escalated doses of these agents can be supported with stem cell transplantation and can produce high rates of complete response and greater survival in patients with relapsed NHL. The quality and duration of responses are greater with radioimmunotherapy when it is used earlier in the course of treatment.

• OSTI ID: 20850088
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 2 Vol. 66; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
ANTIBODIES
ANTIGENS
CHEMOTHERAPY
CLINICAL TRIALS
IODINE 131
LYMPHOMAS
PATIENTS
RADIATION DOSES
RADIOIMMUNOTHERAPY
STEM CELLS